U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H19N3O.ClH
Molecular Weight 317.813
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTOLAMINE HYDROCHLORIDE

SMILES

Cl.CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(O)=CC=C3

InChI

InChIKey=TUEJFGFQYKDAPM-UHFFFAOYSA-N
InChI=1S/C17H19N3O.ClH/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15;/h2-8,11,21H,9-10,12H2,1H3,(H,18,19);1H

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00692 | https://www.drugs.com/pro/phentolamine.html | http://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392 | https://www.ncbi.nlm.nih.gov/pubmed/26180030

Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur.

Originator

Tappi, G.|Forni, P.V.
3
Sources: Annali di Chimica Applicata (1948), 38, 602-13.

Approval Year

1952
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 3.7 nM [Kd]
Antagonist
2778
 16.6 nM [Kd]
Antagonist
2778
 5.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Primary
Approved
8429
REGITINE

Approved Use

Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test.

Launch Date

1952
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
67.05 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197.59 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.32 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/24452521
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENTOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Disc. AE: Rhinitis, Vomiting...
AEs leading to
discontinuation/dose reduction:
Rhinitis
Vomiting
Nausea
Diarrhea
Headache
Dizziness
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Disc. AE: Dyspnea, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Dyspnea (0.84%)
Tachycardia (0.84%)
Epistaxis (0.84%)
Cephalgia (0.84%)
Flushing (serious, 0.84%)
Chest pain (serious, 0.84%)
Shortness of breath (serious, 0.84%)
Tachycardia (serious, 0.84%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Disc. AE: Myocardial infarction, Cerebrovascular spasm...
AEs leading to
discontinuation/dose reduction:
Myocardial infarction
Cerebrovascular spasm
Cerebral vascular occlusion
Hypotension
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
AEs

AEs

AESignificanceDosePopulation
Diarrhea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Dizziness Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Headache Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Nausea Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Rhinitis Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Tachycardia Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Vomiting Disc. AE
80 mg 10 times / month multiple, oral
Highest studied dose
Dose: 80 mg, 10 times / month
Route: oral
Route: multiple
Dose: 80 mg, 10 times / month
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
unhealthy, 26–83
n = 691
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 26–83
Sex: M
Population Size: 691
Sources:
https://pubmed.ncbi.nlm.nih.gov/12152116
Page: p.268
Cephalgia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Dyspnea 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Epistaxis 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Tachycardia 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Chest pain serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Flushing serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Shortness of breath serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Tachycardia serious, 0.84%
Disc. AE
40 mg 1 times / day multiple, oral
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
unhealthy, 28–80
n = 119
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 28–80
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/12161768
Page: S51
Cerebral vascular occlusion Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Cerebrovascular spasm Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Hypotension Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Myocardial infarction Disc. AE
5 mg single, intravenous|intramuscular
Recommended
Dose: 5 mg
Route: intravenous|intramuscular
Route: single
Dose: 5 mg
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
unhealthy
Health Status: unhealthy
Condition: Pheochromocytoma
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8081
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8081
ChemicalBook
CB6665216
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6665216
MolPort
MolPort-000-771-097
https://www.molport.com/shop/molecule-link/MolPort-000-771-097
MolPort
MolPort-001-783-569
https://www.molport.com/shop/molecule-link/MolPort-001-783-569
ZINC
ZINC000000020251
http://zinc15.docking.org/substances/ZINC000000020251
eMolecules
31790003
https://www.emolecules.com/cgi-bin/more?vid=31790003
eMolecules
975745
https://www.emolecules.com/cgi-bin/more?vid=975745
PubMed

PubMed

TitleDatePubMed
Positive phentolamine test in hypertension induced by a nasal decongestant.
1969 Apr 17
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats.
1975
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors.
1977 Apr
[Effect of several neuroleptic, adreno-, sympatho- and cholinolytic substances on the development of experimental cerebral edema induced by nicotine].
1977 May-Jun
Central action of narcotic analgesics. Part III. The role of endogenous noradrenaline in hyperactivity induced by morphine or fentanyl in mice.
1978 Jul-Aug
DDT-induced myoclonus: serotonin and alpha noradrenergic interaction.
1979 Feb
Effects of pretreatment with 6-hydroxydopamine or noradrenergic receptor blockers on the clonidine-induced distruption of conditioned avoidance responding.
1979 Sep 1
Noradrenergic influences on sound-induced seizures.
1980 Aug
Noninvasive assessment of load reduction in chronic congestive heart failure patients.
1981 Aug
Pharmacological characterisation of the alpha-adrenoceptors responsible for a decrease of blood pressure in the nucleus tractus solitarii of the rat.
1981 Sep
Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy.
1983 Apr
A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension.
1983 May
[Hemodynamic and respiratory effects of phentolamine in pulmonary hypertension secondary to chronic obstructive syndrome].
1985 Jan 19
Ventricular tachycardia induced by clonidine withdrawal.
1985 Jun
Hypertension after epidural meperidine.
1985 Nov
Sympathetic mechanisms in poststenotic myocardial ischemia.
1986
Propranolol antagonizes hypotension induced by alpha-blockers but not by sodium nitroprusside or methacholine.
1989 Feb
An improved vasoactive drug combination for a pharmacological erection program.
1991 Dec
A lethal complication of papaverine-induced priapism.
1991 Jan
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
1992 Jul
Use of phentolamine for cocaine-induced myocardial ischemia.
1992 Jul 30
Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit.
1993 Jul
Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
1993 May
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice.
1993 Oct 15
Reasons for high drop-out rate with self-injection therapy for impotence.
1994 Sep
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
1995 Jun
Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat.
1995 Mar
Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline.
1996 Apr 22
Cocaine-associated myocardial infarction.
1996 Aug
Neural mechanism of pressor action of nitric oxide synthase inhibitor in anesthetized monkeys.
1996 Sep
[The vasodilation and its mechanism of C-type natriuretic peptide].
2001 May
Technical aspects of harvesting the radial artery with the harmonic scalpel.
2003
Effects of intravenous dobutamine on coronary vasomotion in humans.
2003 Nov 5
Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane.
2004 Aug
[Lessons learned from anesthetic management of pheochromocytoma resection: a report of three cases].
2004 Dec
Phentolamine bioequivalence study.
2004 Jan
Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors.
2004 Sep 1
Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system.
2005 May
Sympathetic neurotransmission in the rat testicular capsule: functional characterization and identification of mRNA encoding alpha1-adrenoceptor subtypes.
2006 Aug 14
Evaluation and management of the patient who has cocaine-associated chest pain.
2006 Feb
Phentolamine therapy for cocaine-association acute coronary syndrome (CAACS).
2006 Sep
[Effect of morphine chloride on contractility of small intestinal muscle in vitro or in vivo and its mechanisms].
2008 May
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
2009 Nov 1
Local and systemic toxicity of intraoral submucosal injections of phentolamine mesylate (OraVerse).
2009 Winter
Limited clinical value of bacterial cocaine esterase in cocaine toxicity.
2010 May
Phentolamine mesylate for accelerating recovery from lip and tongue anesthesia.
2010 Oct
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.
2011 Jul
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Insights into the mechanisms mediating hyperglycemic and stressogenic outcomes in rats treated with monocrotophos, an organophosphorus insecticide.
2012 Mar 29
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.
2012 Oct
Patents

Patents

CH262433
3

Sample Use Guides

In Vivo Use Guide
Prevention or control of hypertensive episodes in the patient with pheochromo-cytoma. For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine mesylate (1 mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary. During surgery, Phentolamine mesylate (5 mg for adults, 1 mg for children) is administered intravenously as indicated, to help prevent or control paroxysms of hypertension, tachycardia, respiratory depression, convulsions, or other effects of epinephrine intoxication.
Route of Administration: Other
In Vitro Use Guide
Cancer cell lines, PC-3, DU-145, NCI/ADR-RES, and SKOV3 were used for activity evaluation. Cells were seeded in 96-well plates. After 24 hr, cells were fixed with 10% trichloroacetic acid (TCA) representing cell population at time zero (T0). After additional incubation of 0.1% DMSO or phentolamine for 48 hr, cells were fixed with 10% TCA and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells. Unbound SRB was washed out. SRB bound cells were solubilized with 10mM Trizma base.
Name Type Language
PHENTOLAMINE HYDROCHLORIDE
MI   USP-RS   WHO-DD  
Common Name English
Phentolamine hydrochloride [WHO-DD]
Common Name English
PHENOL, 3-(((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)(4-METHYLPHENYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
M-(N-(2-IMIDAZOLIN-2-YLMETHYL)-P-TOLUIDINO)PHENOL MONOHYDROCHLORIDE
Common Name English
PHENTOLAMINE HYDROCHLORIDE [MI]
Common Name English
PHENOL, 3-(((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)(4-METHYLPHENYL)AMINO), MONOHYDROCHLORIDE
Common Name English
PHENTOLAMINE HCL
Common Name English
NSC-757431
Code English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
Code System Code Type Description
CAS
73-05-2
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
SMS_ID
100000086574
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL597
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-793-5
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
NSC
757431
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
PUBCHEM
657359
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID40223271
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
FDA UNII
86DRW83R1H
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
NCI_THESAURUS
C80007
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
EVMPD
SUB22729
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY
MERCK INDEX
m8646
Created by admin on Fri Dec 15 15:02:23 GMT 2023 , Edited by admin on Fri Dec 15 15:02:23 GMT 2023
PRIMARY Merck Index
ACTIVE MOIETY
Structure of PHENTOLAMINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966